Interleukin-33 levels in gingival crevicular fluid, saliva, or plasma do not differentiate chronic periodontitis

Journal of Periodontology

Volumn 83, Issue 3, 2012, Pages 362-368

  Buduneli, Nurcan ^a   Özcxaka, Özgün ^a   Nalbantsoy, Aysxe ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Gingival crevicular fluid; Human; IL 33 protein; Inflammation; Periodontal diseases; Plasma; Saliva

Indexed keywords

BIOLOGICAL MARKER; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ALVEOLAR BONE LOSS; ARTICLE; BLOOD; CHEMISTRY; CHRONIC PERIODONTITIS; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; GINGIVA BLEEDING; GINGIVITIS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PERIODONTAL DISEASE; PERIODONTAL POCKET; PERIODONTICS; PERIODONTIUM; SALIVA; TOOTH RADIOGRAPHY;

ADULT; AGED; ALVEOLAR BONE LOSS; BIOLOGICAL MARKERS; CHRONIC PERIODONTITIS; FEMALE; GINGIVAL CREVICULAR FLUID; GINGIVAL HEMORRHAGE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL INDEX; PERIODONTAL POCKET; PERIODONTIUM; RADIOGRAPHY, BITEWING; SALIVA;

EID: 84857820667     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2011.110239     Document Type: Article

References (39)

1. Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 2007;149:217-225. (Pubitemid 47063063)
2. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23: 479-490. (Pubitemid 41587888)
3. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1- like cytokine ligand for ST2 receptor, is a chromatinassociated nuclear factor in vivo. Proc Natl Acad Sci USA 2007;104:282-287. (Pubitemid 46068023)
4. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008;105:10913-10918.
5. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007;37:2779-2786. (Pubitemid 47578297)
6. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007;40:216-225. (Pubitemid 350213434)
7. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009;106:9021-9026.
8. Nile CJ, Barksby E, Jitprasertwong P, Preshaw PM, Taylor JJ. Expression and regulation of interleukin- 33 in human monocytes. Immunology 2010;130: 172-180.
9. Gemmell E, Seymour GJ. Immunoregulatory control of Th1/Th2 cytokine profiles in periodontal disease. Periodontol 2000 2004;35:21-41. (Pubitemid 41742817)
10. Dutzan N, Gamonal J, Silva A, Sanz M, Vernal R. Overexpression of forkhead box P3 and its association with receptor activator of nuclear factor-kappa B ligand, interleukin (IL) -17, IL-10 and transforming growth factor-beta during the progression of chronic periodontitis. J Clin Periodontol 2009;36:396-403.
11. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20-38. (Pubitemid 351986169)
12. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009;5:667-676.
13. Buduneli N, Biyikoǧlu B, Sherrabeh S, Lappin DF. Saliva concentrations of RANKL and osteoprotegerin in smoker versus non-smoker chronic periodontitis patients. J Clin Periodontol 2008;35:846-852.
14. Buduneli N, Buduneli E, Kütükcxüler N. Interleukin-17, RANKL, and osteoprotegerin levels in gingival crevicular fluid from smoking and non-smoking patients with chronic periodontitis during initial periodontal treatment. J Periodontol 2009;80:1274-1280.
15. Ö zcxaka Ö , Nalbantsoy A, Köse T, Buduneli N. Plasma osteoprotegerin levels are decreased in smoker chronic periodontitis patients. Aust Dent J 2010;55:405-410.
16. Mun SH, Ko NY, Kim HS, et al. Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes. Cell Mol Life Sci 2010;67:3883-3892.
17. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
18. Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993;694:72-77. (Pubitemid 23298232)
19. Boström L, Linder LE, Bergström J. Smoking and cervicular fluid levels of IL-6 and TNF-alpha in periodontal disease. J Clin Periodontol 1999;26:352-357.
20. Ö zcxaka Ö , Nalbantsoy A, Buduneli N. Salivary osteocalcin levels are decreased in smoker chronic periodontitis patients. Oral Dis 2011;17:200-205.
21. Ö zcxaka Ö , Bicxakci N, Pussinen P, Sorsa T, Köse T, Buduneli N. Smoking and matrix metalloproteinases, neutrophil elastase and myeloperoxidase in chronic periodontitis. Oral Dis 2011;17:68-76.
22. Kaufman E, Lamster IB. Analysis of saliva for periodontal diagnosis - a review. J Clin Periodontol 2000; 27:453-465.
23. Edgar WM. Saliva: its secretion, composition and functions. Br Dent J 1992;172:305-312.
24. Chapple IL, Mason GI, Garner I, et al. Enhanced chemiluminescent assay for measuring the total antioxidant capacity of serum, saliva and crevicular fluid. Ann Clin Biochem 1997;34:412-421. (Pubitemid 27332315)
25. Lamster IB, Oshrain RL, Gordon JM. Enzyme activity in human gingival crevicular fluid: considerations in data reporting based on analysis of individual crevicular sites. J Clin Periodontol 1986;13:799-804.
26. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007;179:2051-2054.
27. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: A review. J Periodontol 2005; 76(Suppl. 11)2066-2074. (Pubitemid 41748955)
28. Savage A, Eaton KA, Moles DR, Needleman IA. A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol 2009;36:458-467.
29. Buduneli N, Kinane DF. Host-derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis. J Clin Periodontol 2011; 38(Suppl. 11):85-105.
30. Loo JA, Yan W, Ramachandran P, Wong DT. Comparative human salivary and plasma proteomes. J Dent Res 2010;89:1016-1023.
31. Taubman MA, Valverde P, Han X, Kawai T. Immune response: The key to bone resorption in periodontal disease. J Periodontol 2005; 76(Suppl. 11)2033-2041. (Pubitemid 41748950)
32. O'Neill LA, Dinarello CA. The IL-1 receptor/toll-like receptor superfamily: Crucial receptors for inflammation and host defense. Immunol Today 2000;21:206-209. (Pubitemid 30259023)
33. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001;164:277-281. (Pubitemid 34001295)
34. Tajima S, Oshikawa K, Tominaga S, Sugiyama Y. The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest 2003;124:1206-1214. (Pubitemid 37290028)
35. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010;40:200-208.
36. Sakashita M, Yoshimoto T, Hirota T, et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008;38:1875-1881.
37. Yang Z, Liang Y, Xi W, Li C, Zhong R. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med 2011;11: 75-80.
38. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011 June 4. [Epub ahead of print].
39. Mok MY, Huang FP, Ip WK, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2010;49:520-527.